Novel quinazoline derivatives possessing activity as estrogen receptor beta (ER.beta.) modulators are provided which have the general formula I ##STR00001## wherein X is O or S; A and B are each independently CR''' or N; R, R' and R'' are each independently hydrogen, alkyl, benzyl, p-methoxybenzyl, allyl, or Si(R.sub.4).sub.3, wherein at least one of R, R' and R'' is hydrogen; R''' is hydrogen, halogen, CF.sub.3, OR.sub.5, S(O).sub.nR.sub.6, NR.sub.7R.sub.8, cycloalkyl or alkyl; R.sub.1, R.sub.2 and R.sub.3 are each independently hydrogen, halogen, CF.sub.3, OR.sub.5, S(O).sub.nR.sub.6, NR.sub.7R.sub.8, cycloalkyl or alkyl; R.sub.4 is a alkyl; R.sub.5, R.sub.6, R.sub.7 and R.sub.8 in each functional group are each independently hydrogen, cycloalkyl or alkyl; and n is an integer from 0 to 2. In addition, a method is provided for preventing, inhibiting or treating the progression or onset of pathological conditions associated with the estrogen receptor and to pharmaceutical compositions containing such compounds.

 
Web www.patentalert.com

< Antibodies specific for sclerostin and methods of screening and use therefor

> Polypeptide Hormone Phosphatonin

~ 00438